Personal
Professional
Research
Personal Professional Research Sign Up Login Pro Login
Research CA 15-3
Tumor / Cancer screening tests

CA 15-3

Optimal Result: 0 - 31 U/mL.

Cancer antigen 15-3 (CA 15-3) is a tumor marker used to monitor the response to breast cancer treatment and detect disease recurrence. The reference range of serum CA 15-3 is typically less than 30 U/mL, but the upper limit varies based on the specific laboratory and test kit used. It's important to note that results obtained from different assay kits, methods, or laboratories should not be used interchangeably.

CA 15-3 levels are commonly employed to monitor metastatic breast cancer during active therapy. However, these levels must be used in conjunction with the patient's history, physical examination, and diagnostic imaging. A decrease in marker levels during treatment may indicate a positive response to therapy, while stable or increasing levels despite adequate treatment may suggest treatment failure or disease recurrence.

Additionally, CA 15-3 measurement can be used to survey disease recurrence after treatment of metastatic breast cancer. In cases without measurable disease, an increase in CA 15-3 levels could indicate treatment failure. However, it's worth noting that CA 15-3 levels can temporarily rise during the first 4-6 weeks of starting therapy, and this transient rise usually does not correlate with disease progression.

Higher CA 15-3 levels have been associated with more advanced stages of breast cancer or larger tumor burden. When the tumor produces CA 15-3, marker levels will increase as the tumor grows. The highest levels of CA 15-3 are often observed in metastatic breast cancer, especially when metastases are present in the liver or bones. However, CA 15-3 can be low or absent in some cases since not all breast cancers produce this marker, and early-stage breast cancers may not have detectable CA 15-3 levels. As a result, normal CA 15-3 levels do not guarantee the absence of localized or metastatic breast cancer.

Studies have shown that in 62% of patients treated for early breast cancer in whom metastases were found, CA 15-3 levels were above 30 U/mL at the time of metastases discovery. In 37% of patients, the higher CA 15-3 level was the first sign leading to the diagnosis of metastases, with liver and bone metastases being the most common.

It's essential to consider that elevated CA 15-3 levels can also be seen in healthy individuals, as well as in benign and other malignant conditions. Consequently, elevated levels need to be interpreted within the context of the patient's medical history, physical examination, diagnostic imaging, and laboratory workup.

While CA 15-3 testing can provide valuable information in monitoring response to treatment and detecting disease recurrence, it has limitations. The sensitivity of CA 15-3 is low in early-stage breast cancer, and it may not be detected in all breast cancers. Moreover, its overall specificity is limited, making it challenging to reliably screen, diagnose, or stage breast cancer based solely on CA 15-3 levels.

In conclusion, CA 15-3 is a useful marker for monitoring breast cancer treatment response and detecting disease recurrence, particularly in cases of metastatic breast cancer. However, it should be used in combination with other clinical and imaging assessments for a comprehensive evaluation of the patient's condition. Furthermore, its limitations should be considered when interpreting the results, and more research is needed to explore its full clinical utility and impact on patient outcomes.

References:

De Cock L, Heylen J, Wildiers A, Punie K, Smeets A, Weltens C, Neven P, Billen J, Laenen A, Wildiers H. Detection of secondary metastatic breast cancer by measurement of plasma CA 15.3. ESMO Open. 2021 Aug;6(4):100203. doi: 10.1016/j.esmoop.2021.100203. Epub 2021 Jul 13. PMID: 34271308; PMCID: PMC8282974.

Bon GG et al. Clinical and technical evaluation of ACS™BR serum assay of MUC1 gene-derived glycoprotein in breast cancer, and comparison with CA 15-3 assays. Clinical Chemistry. 1997. 43(4):585-593.

Wu JT. Expression of monoclonal antibody-defined tumor markers in four carcinomas. Ann Clin Lab Sci. 1989 Jan-Feb;19(1):17-26. PMID: 2916833.

Duffy MJ, Shering S, Sherry F, McDermott E, O'Higgins N. CA 15-3: a prognostic marker in breast cancer. Int J Biol Markers. 2000 Oct-Dec;15(4):330-3. doi: 10.1177/172460080001500410. PMID: 11192829.

Klee GG, Schreiber WE. MUC1 gene-derived glycoprotein assays for monitoring breast cancer (CA 15-3, CA 27.29, BR): are they measuring the same antigen? Arch Pathol Lab Med. 2004 Oct;128(10):1131-5. doi: 10.5858/2004-128-1131-MGGAFM. PMID: 15387710.

Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, Somerfield MR, Hayes DF, Bast RC Jr; American Society of Clinical Oncology. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007 Nov 20;25(33):5287-312. doi: 10.1200/JCO.2007.14.2364. Epub 2007 Oct 22. PMID: 17954709.

Ebeling FG, Stieber P, Untch M, Nagel D, Konecny GE, Schmitt UM, Fateh-Moghadam A, Seidel D. Serum CEA and CA 15-3 as prognostic factors in primary breast cancer. Br J Cancer. 2002 Apr 22;86(8):1217-22. doi: 10.1038/sj.bjc.6600248. PMID: 11953875; PMCID: PMC2375330.

Wang G, Qin Y, Zhang J, Zhao J, Liang Y, Zhang Z, Qin M, Sun Y. Nipple discharge of CA15-3, CA125, CEA and TSGF as a new biomarker panel for breast cancer. Int J Mol Sci. 2014 May 28;15(6):9546-65. doi: 10.3390/ijms15069546. PMID: 24879526; PMCID: PMC4100109.

Kokko R, Holli K, Hakama M. Ca 15-3 in the follow-up of localised breast cancer: a prospective study. Eur J Cancer. 2002 Jun;38(9):1189-93. doi: 10.1016/s0959-8049(01)00429-4. PMID: 12044504.

Nicolini A, Tartarelli G, Carpi A, Metelli MR, Ferrari P, Anselmi L, Conte M, Berti P, Miccoli P. Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases. BMC Cancer. 2006 Nov 20;6:269. doi: 10.1186/1471-2407-6-269. PMID: 17116247; PMCID: PMC1684262.

Kruse V, Van de Wiele C, Borms M, Maes A, Pottel H, Sathekge M, Cocquyt V. CA 15.3 measurements for separating FDG PET/CT positive from negative findings in breast carcinoma recurrence. Factors influencing the area under the ROC curve. Nuklearmedizin. 2014 Aug 6;53(4):131-8. doi: 10.3413/Nukmed-0634-13-12. PMID: 25100557.

Cervino AR, Saibene T, Michieletto S, Ghiotto C, Bozza F, Saladini G, Evangelista L. Correlation between cancer antigen 15.3 value and qualitative and semiquantitative parameters of positron emission tomography/computed tomography in breast cancer patients. Curr Radiopharm. 2014;7(1):20-8. doi: 10.2174/1874471007666140515111134. PMID: 24836946.

Nicolini A, Carpi A, Ferrari P, Morganti R, Mazzotti V, Barak V, Duffy MJ. An individual reference limit of the serum CEA-TPA-CA 15-3 tumor marker panel in the surveillance of asymptomatic women following surgery for primary breast cancer. Cancer Manag Res. 2018 Dec 13;10:6879-6886. doi: 10.2147/CMAR.S177522. PMID: 30588093; PMCID: PMC6300365.

Heylen J, Punie K, Smeets A, Neven P, Weltens C, Laenen A, Wildiers H. Elevated CA 15.3 in Newly Diagnosed Breast Cancer: A Retrospective Study. Clin Breast Cancer. 2022 Aug;22(6):579-587. doi: 10.1016/j.clbc.2022.04.007. Epub 2022 Apr 30. PMID: 35668001.

Sturgeon C. Practice guidelines for tumor marker use in the clinic. Clin Chem. 2002 Aug;48(8):1151-9. PMID: 12142367.

What does it mean if your CA 15-3 result is too high?

Elevation of CA 15-3 levels can be seen in healthy individuals, in benign conditions, and in other malignant conditions. However, CA 15-3 levels tend to remain relatively stable over time in benign conditions; thus, elevated levels need to be interpreted within the context of the patient’s history and physical examination, diagnostic imaging, and laboratory workup.

Benign causes of elevated CA 15-3 levels are as follows:

→ Chronic hepatitis

→ Liver cirrhosis

→ Tuberculosis

→ Sarcoidosis

→ Benign breast disease

→ Pelvic inflammatory disease

→ Endometriosis

→ Systemic lupus erythematosus

→ Lactation and pregnancy

Malignant causes of elevated CA 15-3 levels are as follows:

→ Small cell lung cancer

→ Non-small cell lung cancer

→ Liver cancer

→ Colon cancer

→ Ovarian cancer

→ Endometrial cancer

→ Pancreatic cancer

Frequently asked questions

Healthmatters is a highly-personalized health dashboard.

Instead of searching for your lab results in different places or tracking them down from different providers, Healthmatters houses, organizes, and interprets them all in one central location.

With a Healthmatters account, you can dive into the details of each biomarker and gain insights into the meaning behind your medical test data, anytime, anywhere.

For our professional users, Healthmatters provides intuitive tools that not only streamline analysis but also save valuable time when delving into your client's lab report history.

Healthmatters.io personal account provides in-depth research on 4000+ biomarkers, including information and suggestions for test panels such as, but not limited to:

  • The GI Effects® Comprehensive Stool Profile,
  • GI-MAP,
  • The NutrEval FMV®,
  • The ION Profile,
  • Amino Acids Profile,
  • Dried Urine Test for Comprehensive Hormones (DUTCH),
  • Organic Acids Test,
  • Organix Comprehensive Profile,
  • Toxic Metals,
  • Complete Blood Count (CBC),
  • Metabolic panel,
  • Thyroid panel,
  • Lipid Panel,
  • Urinalysis,
  • And many, many more.

You can combine all test reports inside your Healthmatters account and keep them in one place. It gives you an excellent overview of all your health data. Once you retest, you can add new results and compare them.

If you are still determining whether Healthmatters support your lab results, the rule is that if you can test it, you can upload it to Healthmatters.

While we work with many popular labs, we welcome reports from lots of other places too.

It's as simple as this: if you can get a test done, you can upload it to Healthmatters and we can interpret results from any lab out there. If laboratories can analyze it, we can interpret it.

If you’re on the hunt for a specific biomarker, contact us and we'll add it to our database. Anything from blood, urine, saliva, or stool can be uploaded, understood, and tracked with your Healthmatters account.

There are two ways to add your test reports to your Healthmatters account. One option is to input the data using the data entry forms. The other method is to utilize our "Data entry service."

Our data entry forms offer an easy, fast, and free way for you to input the reports yourself. Self-entry allows you to add an unlimited number of reports at no cost. We make the self-entry process user-friendly, providing dozens of templates that pre-populate the most popular laboratory panels and offering instant feedback on entered values.

For those who prefer assistance, we offer a "Data entry service" to help you input your data. Simply attach an image or file of your lab test results, and a qualified team member from our data entry team will add the results for you.

We support various file types, including PDFs, JPGs, or Excel. This service is particularly useful if you have many reports to upload or if you're too busy to handle the data entry yourself.

Our special data entry service makes it easy to add your results to your private dashboard. Just attach an image or a file of your lab test results, and our skilled data entry team will do the work for you. It's all done by humans, ensuring that your data is entered accurately and with personal care for each client.

Depending on your account, the data entry service can be included for free or come at an additional cost of $15 per report.

For users on the Complete monthly plan, the first report is entered free of charge, and each additional report incurs a fee of $15.

Unlimited account holders enjoy the entry of ten reports without charge. Subsequent reports are subject to a $15 fee per report.

Additionally, users on the Complete plan can upgrade to a yearly subscription from the account settings. The annual subscription includes a data entry service for five reports.

The Unlimited plan is a one-time purchase for $250, and it covers your account for a lifetime with no additional payments.

For the Complete plan, the cost is $15 per month. You have the flexibility to cancel it anytime through your account settings, ensuring no further payments. To avoid charges, remember to cancel at least a day before the renewal date. Once canceled, the subscription remains active until the end of the current billing cycle.

Additionally, you can upgrade to the yearly Advanced plan from within your account. The annual cost is $79, and it comes with a data entry service for five reports.

You can always upgrade to a lifetime version with a prorated price from a monthly or yearly subscription.

Simply log in and navigate to your account settings to cancel your subscription. Scroll down to locate the 'Cancel' button at the bottom of the page. Ensure you cancel at least one day before the renewal date to prevent any charges. Once cancellation is requested, the subscription remains active until the conclusion of the current billing cycle.

Our goal has been to make your Healthmatters account as intuitive as possible.

We’ve crafted multiple ways for you to navigate your data, whether you're glancing at a single report or delving into your historical test reports.

1. Graph View:

Dive into a visual journey with our biomarker graphs, showcasing over 40 data points. Combining years of results unveils trends, empowering you to make informed decisions. Our visualization tools make it a breeze to compare and understand changes over time, even if your results are from different labs. A search function and filters simplify the exploration of extensive data, allowing you to focus on what needs attention.

2. All Tests View

Explore neatly organized reports on a timeline, highlighting crucial details like dates, critical results, and lab/panel names. Each report opens up to reveal in-depth descriptions and additional recommendations for each biomarker. The history of previous results is just a click away, and you can download a comprehensive report for deeper insights. Color-coded and user-friendly, it's designed for easy reading, understanding, and navigation.

3. Table View:

For a holistic view of all biomarkers side by side, our table view is your go-to. Results are neatly displayed in a categorized and dated table, ideal for those with an extensive test history. Utilize sorting, filters, and color-coding to enhance your analysis and gain extra insights.

Yes, you can download information from your account. We can compile your labs into a CSV file. To download all your labs, you can go to Account Settings, and at the bottom of the page, you will find a link to download your information.

Yes, you can print your report. To do so, navigate to "All tests" and open the report you wish to print. You'll find a print button in the right corner of the report. Click on it, and your browser's print window will open. If you prefer to print in a bigger typeface, adjust the scale using the print window settings.

Yes, you can! We highly recommend activating Two-Factor Authentication (2FA) for your account. To do so, please navigate to the "Profile and Security" section of your account, where you will find instructions for activating 2FA.

Yes, you can. When entering values for the biomarker, you will see an "Edit Range" button. Click this button, and you'll have the option to enter a custom range.

A personal account is all about keeping your own lab test results in check. It's just for you and your personal use.

The professional account is designed for health professionals who wish to track and organize their clients' laboratory results.

To learn more about Healthmatters Pro, please refer to the professional page.

Use promo code to save 10% off any plan.


We implement proven measures to keep your data safe.

At HealthMatters, we're committed to maintaining the security and confidentiality of your personal information. We've put industry-leading security standards in place to help protect against the loss, misuse, or alteration of the information under our control. We use procedural, physical, and electronic security methods designed to prevent unauthorized people from getting access to this information. Our internal code of conduct adds additional privacy protection. All data is backed up multiple times a day and encrypted using SSL certificates. See our Privacy Policy for more details.

Navigate to Tumor / Cancer screening tests

Popular search

Alpha Fetoprotein (AFP), CA 125, CA 15-3, CA 19-9, CA 27.29, CA 72-4, Carcinoembryonic Antigen (CEA), CD19, Chromogranin A (CgA), CYFRA 21-1 (Cytokeratin 19 Fragment), Leukemia/Lymphoma/Myeloma Panel by Flow Cytometry, Matrix Metalloproteinase 9 (MMP 9), MMP-9 (Matrix Metalloproteinase-9), Neuron-specific Enolase (NSE), Neurone Specific Enolase, PapIG, HPV, rfx 16/18, Prostate Cancer Risk Score, Prostate Specific Antigen (PSA), PSA, % Free, S100, Squamous Cell Carcinoma, Total Prostate Specific Antigen (TPSA), Tumor Necrosis Factor-Alpha, Highly Sensitive, Urinary Bladder Cancer Antigen